<DOC>
	<DOCNO>NCT02004119</DOCNO>
	<brief_summary>This study randomize double-blind placebo-controlled study evaluate efficacy safety oral KHK4577 6 week patient atopic dermatitis . Pharmacokinetics KHK4577 also assess .</brief_summary>
	<brief_title>Phase 2 Study KHK4577</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subject sign voluntarily write informed consent form participate study . Subject diagnose atopic dermatitis accord Guidelines Management Atopic Dermatitis ( 2009 ) . Rajka &amp; Langeland criterion &gt; /= 4.5 screen visit Investigator 's Global Assessment ( IGA ) score &gt; /= 3 screen visit Evidence skin disorders/conditions would interfere assessment effect study drug . Subject receive photochemotherapy systemic immunosuppressant within 2 week prior inform consent . Subject active infectious disease ( except localize infection ) need treat systemic antibiotic ( eg . antibacterial , antifungal antiviral drug ) within 4 week prior inform consent . Subject complication / history drug abuse alcoholism . Subject drug allergy history allergic reaction drug medicine . Subject significant concurrent medical condition define study protocol . Subject breastfeeding , pregnant planning become pregnant study period .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>